Literature DB >> 15300360

Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats.

Christian Höcht1, Carla Di Verniero, Javier A W Opezzo, Carlos A Taira.   

Abstract

The present study addressed possible alterations in the pharmacodynamic and pharmacokinetic properties of the beta1-adrenoceptor antagonist metoprolol in experimental hypertension induced by abdominal aortic coarctation (ACo). Metoprolol's pharmacokinetics and its relationship with its in vivo chronotropic and blood pressure effect were studied using the microdialysis technique. A pharmacokinetic-pharmacodynamic model with a separate effect compartment was used to analyse the data. No differences were found in the calculated pharmacokinetic parameters between sham-operated (SO) and ACo rats. Bradycardia was observed after the i.v. injection of metoprolol (3 or 10 mg/kg) without differences between the experimental groups. The decrease of mean arterial pressure (DeltaMAP) induced by metoprolol was greater in ACo than in SO rats: SO: -14+/-2 mmHg, n=5; ACo: -26+/-4 mmHg, n=5, P<0.05. The dissociation constant (expressed as pKb) of metoprolol and its inverse agonistic activity were studied in isolated atria. The pKb of metoprolol was similar in both groups of animals (SO: 7.49+/-0.20; ACo: 7.19+/-0.23). The inverse agonistic activity of metoprolol on spontaneous beating of isolated atria was established by means of a concentration/response curve. There were no differences in maximum response (Emax; SO: -28+/-2.0%, n=5; ACo: -27+/-4%, n=5) or the concentration eliciting a half-maximal effect (pEC50) (SO: 4.9+/-0.2, n=5; ACo: 5.2+/-0.2, n=5) between the experimental groups. These results suggest that chronic ACo does not modify the beta-adrenoceptor affinity of metoprolol or its inverse agonistic activity. Moreover, there was no difference in the in vivo chronotropic effect between the experimental groups, indicating the absence of cardiac sympathetic over-activity in this model of hypertension. The pharmacokinetic results suggest that the metabolism of metoprolol is not affected in chronic ACo rats. In addition, the greater sensitivity to the depressor effect of metoprolol in ACo rats in the chronic hypertensive stage suggests a participation of the beta-adrenoceptors in the maintenance of hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300360     DOI: 10.1007/s00210-004-0945-2

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique.

Authors:  J A Opezzo; C Höcht; C A Taira; G F Bramuglia
Journal:  Pharmacol Res       Date:  2001-02       Impact factor: 7.658

2.  Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium.

Authors:  C Maack; S Tyroller; P Schnabel; B Cremers; E Dabew; M Südkamp; M Böhm
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Relation of propranolol plasma level to beta-blockade during oral therapy.

Authors:  R Zacest; J Koch-Weser
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

4.  A method for production of experimental hypertension in rats.

Authors:  J M Rojo-Ortega; J Genest
Journal:  Can J Physiol Pharmacol       Date:  1968-11       Impact factor: 2.273

5.  The effects of a cardioselective (metoprolol) and a nonselective (propranolol) beta-adrenergic blocker on the response to dynamic exercise in normal men.

Authors:  J Sklar; G D Johnston; P Overlie; J G Gerber; H L Brammell; J Gal; A S Nies
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

6.  Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia.

Authors:  L Brynne; M O Karlsson; L K Paalzow
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

7.  Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.

Authors:  C Maack; B Cremers; M Flesch; A Höper; M Südkamp; M Böhm
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

8.  Pharmacokinetic-pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat.

Authors:  X X Yin; Y D Zhang; J P Luo; X P Huang; J P Shen; Y Ding; D K Huang
Journal:  Zhongguo Yao Li Xue Bao       Date:  1997-03

Review 9.  Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.

Authors:  Ali Ahmed
Journal:  Eur J Heart Fail       Date:  2003-12       Impact factor: 15.534

10.  Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.

Authors:  M Esler; A Zweifler; O Randall; V DeQuattro
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

View more
  3 in total

1.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study.

Authors:  Christian Höcht; Carla Di Verniero; Javier A W Opezzo; Guillermo F Bramuglia; Carlos A Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-30       Impact factor: 3.000

2.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

3.  Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.

Authors:  T J van Steeg; J Freijer; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.